Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 129
Healthy volunteers: no

Brief summary:
To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes post therapy administration.

Detailed description:

Arms:
arm 1: interferon beta-1a arm 2: interferon beta-1b

Interventions: intervention 1: New Formulation of rebif - human interferon beta-1a intervention 2: Interferon beta -1b
Intervention descriptions: intervention 1: New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection. intervention 2: Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.

Protocol document: